New treatments targeting a key protein involved in DNA damage response for cancer therapy
Novel DNA damage response therapeutics targeting replication protein A
This study is looking at a new treatment that targets a protein called RPA, which helps cancer cells respond to DNA damage, and it aims to make cancer therapies work better and be safer for patients by using a special small molecule called NERx 329.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project ID | NIH-10873273 on NIH RePORTER |
What this research studies
This research focuses on developing novel therapeutics that target replication protein A (RPA), a crucial protein involved in the DNA damage response (DDR) pathway, which is important for cancer treatment. The approach aims to exploit the vulnerabilities of cancer cells that experience replication stress, leading to cell death when RPA is inhibited. By using a specific small molecule inhibitor, NERx 329, the research seeks to enhance the effectiveness of cancer therapies while minimizing toxicity. Patients may benefit from personalized treatment strategies that leverage the unique characteristics of their tumors.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers characterized by replication stress and deficiencies in DNA repair mechanisms.
Not a fit: Patients with cancers that do not exhibit replication stress or those who are not responsive to DDR-targeted therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted cancer therapies that improve patient outcomes.
How similar studies have performed: Previous research has shown success with similar approaches targeting DNA damage response pathways, particularly with the use of PARP inhibitors in specific cancer types.
Where this research is happening
Indianapolis, United States
- Indiana University Indianapolis — Indianapolis, United States (Active)
Researchers
- Principal investigator: Turchi, John J. — Indiana University Indianapolis
- Study coordinator: Turchi, John J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.